Default version
Site map
Print
November
30
A CALL FOR COVID-19 R&D HAS ENDED: 69 COMPANIES ASK FOR MORE THAN EUR 43 M FUNDING
Lithuanian Business Support Agency (LVPA) has ended a continuos selection of applications for project COVID-19 R&D. There were 69 applicants asking for EUR 43, 67 m funding to create products and services helping to resolve coronavirus problems.
Financial project COVID-19 R&D seeks to promote country companies investing in R&D. Project‘s budget is set at EUR 30 m.
Maximum funding amount is EUR 1 m, 5 companies asked for it. 1 company asked for minimum - EUR 40,000. LVPA‘s investment management service will undertake selection and come up with recommendations to ministry of economics and innovation, most likely in January, 2021.
„We hope that, with the help of the project, prototypes of badly needed products and technologies are to be created in order to manage risks and problems caused by COVID-19 pandemic, treatment of patients and prevention assured. Creation of such certified products would help companies to improve results and grow, not talking about the demand for products, therefore we will concentrate on quality of evaluation“, – claims LVPA director Aurimas Želvys.
Companies applying would like to create COVID-19 medicines, prototypes of advanced technology perinatal stem cells medicines, lungs ventilation device, robotic medical sample collection and analysis system, etc.
Financial project COVID-19 R&D seeks to promote country companies investing in R&D. Project‘s budget is set at EUR 30 m.
Maximum funding amount is EUR 1 m, 5 companies asked for it. 1 company asked for minimum - EUR 40,000. LVPA‘s investment management service will undertake selection and come up with recommendations to ministry of economics and innovation, most likely in January, 2021.
„We hope that, with the help of the project, prototypes of badly needed products and technologies are to be created in order to manage risks and problems caused by COVID-19 pandemic, treatment of patients and prevention assured. Creation of such certified products would help companies to improve results and grow, not talking about the demand for products, therefore we will concentrate on quality of evaluation“, – claims LVPA director Aurimas Želvys.
Companies applying would like to create COVID-19 medicines, prototypes of advanced technology perinatal stem cells medicines, lungs ventilation device, robotic medical sample collection and analysis system, etc.
Projects should be implemented by December 31, 2021, new products are to be created and certified by then.
